CriticalSelective serotonin reuptake inhibitor (SSRI)×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Paroxetine is a potent and selective inhibitor of serotonin reuptake by brain neurons (paroxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) types A and B and so prevents the inactivation of serotonin, noradrenaline and dopamine inside cells and neurons (tranylcypromine SmPC, AEMPS, section 5.1). Combining drugs that increase serotonin availability with MAO inhibitors can cause serotonin syndrome (tranylcypromine SmPC, AEMPS, section 4.4). The Spanish paroxetine SmPCs contraindicate paroxetine with MAO inhibitors precisely because of this risk (paroxetine SmPC, AEMPS, section 4.5). Tranylcypromine and its metabolites are excreted within 24 hours, but full MAO activity returns only after 3–5 days (tranylcypromine SmPC, AEMPS, section 5.1). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine label, US Food and Drug Administration, FDA, section 5.9). The documents describe no pharmacokinetic interaction for this pair. The overall risk of such interactions with tranylcypromine is low: it strongly inhibits the enzyme CYP2A6, which plays little part in the metabolism of most drugs (tranylcypromine SmPC, AEMPS, section 4.5).
Symptoms
Serotonin syndrome or neuroleptic malignant syndrome rarely occurs with paroxetine, particularly in combination with other serotonergic drugs, and can be life-threatening (paroxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). It presents with hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes including confusion, irritability and extreme agitation progressing to delirium and coma (paroxetine SmPC, AEMPS, section 4.4). According to the US tranylcypromine label, serotonin syndrome may also include hallucinations, fast heart rate, dizziness, sweating, flushing, tremor, overactive reflexes, poor coordination, seizures, nausea, vomiting and diarrhoea (tranylcypromine label, US Food and Drug Administration, FDA, section 5.3). Fatal cases have been reported, including in patients treated with tranylcypromine. When tranylcypromine was combined with serotonin reuptake inhibitors, the picture sometimes resembled neuroleptic malignant syndrome (FDA tranylcypromine label, section 5.3).
Management
The combination is contraindicated. The Spanish tranylcypromine summary of product characteristics (SmPC) prohibits combining tranylcypromine with any selective serotonin reuptake inhibitor. The Spanish paroxetine SmPCs prohibit combining paroxetine with monoamine oxidase (MAO) inhibitors, except linezolid under special conditions, and according to its own SmPC tranylcypromine is an irreversible, non-selective MAO inhibitor (tranylcypromine and paroxetine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 5.1). The US labels agree. The paroxetine label contraindicates paroxetine in patients taking MAO inhibitors or within 14 days of stopping them, and the tranylcypromine label lists this group of antidepressants among contraindicated drugs (paroxetine and tranylcypromine labels, US Food and Drug Administration, FDA, sections 4 and 4.1). Start paroxetine no earlier than 2 weeks after stopping tranylcypromine, with caution and with gradual dose increases (paroxetine SmPC, AEMPS, sections 4.3 and 4.4, and FDA label, section 2.7; tranylcypromine SmPC, AEMPS, section 4.2). The documents give different intervals between stopping paroxetine and starting tranylcypromine: at least one week in the Spanish paroxetine SmPC, at least 14 days in the US paroxetine label, and about 5 half-lives of paroxetine and its active metabolites in the Spanish tranylcypromine SmPC. The half-life of paroxetine is usually about one day (paroxetine SmPC, AEMPS, sections 4.3 and 5.2, and FDA label, section 2.7; tranylcypromine SmPC, AEMPS, section 4.2). If serotonin syndrome occurs, stop paroxetine and start supportive symptomatic treatment (paroxetine SmPC, AEMPS, section 4.4), and stop tranylcypromine and any other serotonergic drugs at once as well (FDA tranylcypromine label, section 5.3). Treat severe serotonin syndrome caused by the interaction in the same way as tranylcypromine poisoning: in intensive care, with close monitoring of pulse, blood pressure, breathing and temperature. For severe agitation and marked muscle rigidity, the SmPC recommends benzodiazepines, and cyproheptadine may be tried to block serotonin receptors (tranylcypromine SmPC, AEMPS, section 4.9). Explain to the patient that after tranylcypromine is stopped, some drugs need a drug-free interval before they can be started (FDA tranylcypromine label, section 17).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Paroxetina (nº registro 59466), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59466 (Frosinor 20 mg, GlaxoSmithKline), revisión 12/2025, secciones 4.3, 4.4 y 4.5